Dermata Therapeutics (DRMA) News Today $5.37 +0.02 (+0.37%) As of 12:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DRMA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Dermata Therapeutics (NASDAQ:DRMA) Shares Up 0.9% - Should You Buy?August 29 at 3:21 AM | americanbankingnews.comDermata Therapeutics Regains Nasdaq Compliance by August 2025August 26 at 2:13 AM | msn.comMaxim Group Cuts Dermata Therapeutics (NASDAQ:DRMA) Price Target to $10.00August 24, 2025 | americanbankingnews.comDermata Therapeutics Reports Positive Phase 3 Trial ResultsAugust 13, 2025 | msn.comDermata Therapeutics, Inc. Common Stock (DRMA) - NasdaqAugust 9, 2025 | nasdaq.comDermata Therapeutics, Inc. (DRMA) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comDermata Therapeutics Inc News (DRMA) - Investing.comJuly 10, 2025 | investing.comDermata Therapeutics: Dermata Receives Notice of Grant of Australian Patent for Topical Botulinum Toxin Treatment for HyperhidrosisJuly 8, 2025 | finanznachrichten.deDermata’s XYNGARI trial hits statistically significant difference at 4 weeksApril 17, 2025 | markets.businessinsider.comDermata Therapeutics files to sell 10.01M shares of common stock for holdersApril 17, 2025 | markets.businessinsider.comDermata Therapeutics: Dermata's XYNGARI Phase 3 Trial Hits Statistically Significant Difference at 4 WeeksApril 15, 2025 | finanznachrichten.deDermata’s XYNGARI(TM) Phase 3 Trial Hits Statistically Significant Difference at 4 WeeksApril 15, 2025 | finance.yahoo.comDermata Therapeutics’ xyngari in acne meets all primary Phase 3 endpointsMarch 28, 2025 | markets.businessinsider.comDermata Therapeutics Shares Surge on Positive Acne Treatment StudyMarch 27, 2025 | marketwatch.comNano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For AcneMarch 27, 2025 | benzinga.comDermata Therapeutics Faces Nasdaq Delisting NoticeMarch 27, 2025 | investing.comDermata shares rise on positive acne treatment trial resultsMarch 27, 2025 | za.investing.comBREAKING: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary EndpointsMarch 27, 2025 | prnewswire.comDermata Therapeutics announces last patient visit in Phase 3 acne trialMarch 4, 2025 | markets.businessinsider.comDermata Announces that Last Patient Completes Last Visit in Pivotal XYNGARI™ Phase 3 STAR-1 Clinical Trial for AcneMarch 4, 2025 | prnewswire.comDermata Therapeutics: Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for HyperhidrosisFebruary 25, 2025 | finanznachrichten.deAPO accepts Dermata’s patent application for DMT410 program for hyperhidrosisFebruary 25, 2025 | markets.businessinsider.comDermata Therapeutics receives notice of acceptance for Australian patentFebruary 25, 2025 | markets.businessinsider.comDermata Therapeutics files to sell 1.94M shares of common stock for holdersJanuary 30, 2025 | markets.businessinsider.comDermata Therapeutics: Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne TreatmentJanuary 28, 2025 | finanznachrichten.deDermata Therapeutics to prices 2M shares at $1.27 in private placementJanuary 23, 2025 | markets.businessinsider.comDermata Therapeutics announces $2.55M private offeringJanuary 22, 2025 | msn.comDermata Therapeutics secures $2.55 million in private placementJanuary 22, 2025 | msn.comDermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)January 21, 2025 | finance.yahoo.comDermata, Revance test new hyperhidrosis treatmentJanuary 21, 2025 | msn.comDermata Therapeutics receives FDA approval for Xyngari proprietary nameDecember 18, 2024 | markets.businessinsider.comDermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for AcneDecember 4, 2024 | finance.yahoo.comDermata Therapeutics to Present at the Life Sciences Investor Forum on Thursday, November 14, 2024November 11, 2024 | globenewswire.comWhy Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving PremarketSeptember 16, 2024 | benzinga.comMaxim cuts Dermata Therapeutics stock target, retains buy on dilution riskAugust 23, 2024 | investing.comDermata Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 7, 2024 | finance.yahoo.com3 Penny Stocks to Watch Now, 8/6/24August 6, 2024 | msn.comDermata Therapeutics (NASDAQ:DRMA) Stock, Short Interest ReportJuly 26, 2024 | benzinga.comDermata Therapeutics (NASDAQ:DRMA) Stock Quotes, Forecast and News SummaryJuly 25, 2024 | benzinga.comActinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer TreatmentJuly 25, 2024 | theglobeandmail.comDermata Therapeutics Shares Are Trading Over 100%: What You Need To KnowJuly 24, 2024 | benzinga.comWhy Is Dermata Therapeutics (DRMA) Stock Up 200% Today?July 24, 2024 | investorplace.comDermata Therapeutics announces warrant exercise and new issuanceMay 19, 2024 | uk.investing.comDRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024May 15, 2024 | investorplace.comDermata Therapeutics, Inc. (DRMAW)February 11, 2024 | ca.finance.yahoo.comPresenting on the Emerging Growth Conference 67 Day 1 on February 7 Register NowFebruary 6, 2024 | finance.yahoo.comDermata Therapeutics Inc DRMAFebruary 4, 2024 | morningstar.comMDermata to Present at the Emerging Growth Conference on February 7, 2024February 1, 2024 | finance.yahoo.comDermata stock soars on patent issuance, partnership talksJanuary 7, 2024 | msn.comDow Turns Lower; ISM Services PMI Falls In DecemberJanuary 5, 2024 | msn.com Get Dermata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DRMA Media Mentions By Week DRMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DRMA News Sentiment▼0.051.03▲Average Medical News Sentiment DRMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DRMA Articles This Week▼40▲DRMA Articles Average Week Get the Latest News and Ratings for DRMA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Dermata Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies NEUP News Today PRPH News Today NXTC News Today SNGX News Today MRKR News Today APM News Today TXMD News Today ALVR News Today EPIX News Today GOVX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DRMA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dermata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dermata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access